

Curriculum Vitae

Name: Dr Jeevan Kumar

Designation: Senior Consultant, Department of Clinical Hematology & BMT,
Tata Medical Centre, Kolkata

Address: Department of Clinical Hematology & BMT,
Tata Medical Center, 14 MAR(EW),
New Town, Rajarhat,
Kolkata-700160

EDUCATION QUALIFICATION

| Degree | Institute | Board/ University |
|--|--|---|
| Clinical Hematology & Bone marrow transplant fellowship | Tata Medical Center | Tata Medical Center, Kolkata, India |
| Doctorate of National Board (DrNB) in Hematology (Gold Medalist) | Sir Ganga Ram Hospital, New Delhi, India | National Board of Examinations, New Delhi, India |
| MD in Internal Medicine | Government Medical College, Amritsar, Punjab, India | Baba Farid University of Health Sciences, Faridkot, Punjab, India |
| MBBS | Indira Gandhi Medical College, Shimla, Himachal Pradesh, India | Himachal Pradesh University, Shimla, Himachal Pradesh, India |

PROFESSIONAL EXPERIENCE

| Period | Name of Institution | Position held |
|----------------|---|---|
| 2016-till date | Tata Medical Center, Kolkata, India | Senior Consultant in Department of Clinical Hematology & Bone Marrow Transplant |
| 2014- 2016 | Tata Medical Center, Kolkata, India | Clinical Hematology & Bone marrow transplant fellowship |
| 2010-2011 | Maharishi Markandeshwar Institute of Medical Sciences and Research, Mullana, Ambala, Haryana, India | Assistant Professor of Internal Medicine |
| 2009-2010 | Indira Gandhi Medical College, Shimla, Himachal Pradesh, India | Senior Resident in Department of Nephrology |
| 2008-2009 | Indira Gandhi Medical College, Shimla, Himachal Pradesh, India | Registrar in Department of Cardiology |
| 2004-2005 | Govt. Medical College & Hospital, Sector 32, Chandigarh, India | Medical Officer in Department of Community Medicine |
| 2002-2003 | Govt. Medical College & Hospital, Sector 32, Chandigarh, India | Junior resident in Department of Pediatrics and Medicine |

THESIS AND RESEARCH

1. “Cytogenetic and Molecular Profile of Acute Myeloid Leukaemia in India” Thesis completed during the degree of Diplomate of National Board in Hematology. Studied cytogenetics along with FLT3 and NPM1 mutations in 44 AML patients.
2. “Evaluation of the clinical efficacy of Ramipril versus combination of Ramipril and Telmisartan in microalbuminuria in stage-II hypertensive patients” Thesis completed during the degree of MD in Medicine.

3. Kumar J, Minhas S, Khillan K, Bhargava M, Aggarwal S. Bortezomib plus dexamethasone induction followed by autologous stem cell transplantation in multiple myeloma: A study from India. *Asian Journal of Medical Sciences*. 2016; 7 (4): 44-48.
4. Kumar J, Khan AA, Saraf A, Bhargava M. Expression of CD20 in B cell precursor acute lymphoblastic leukemia. *Indian J Hematol Blood Transfus*. (Jan –Mar) 2014, 30(1) :16-18; doi: 10.1007/s12288-012- 0216-1.

PAPER PRESENTATIONS

1. Data of multiple myeloma patients from Indian Myeloma academic groupe (IMAGE) Registry: Indian Myeloma Congress 3rd annual conference -2020
2. Autologus stem cell transplantation in Mutliple Myeloma: experience of a single center from Eastern India. SOHO meeting 2019, Houston, US
3. FISH Analysis using CD138 Positively Selected Plasma Cells in Multiple Myeloma: A retrospective study from India. Indian Myeloma Congress 2018
4. Analysis of chronic myeloid leukemia treatment of a tertiary care center. Leukemia Meet 2017- Lessons learnt from the Leukemia Clinics, Kolkata
5. Analysis of 53 patients with Autologous Stem Cell Transplantation for Multiple Myeloma from a tertiary care center in Eastern India. 16th International Myeloma Workshop, New Delhi, March 2017
6. “Autologus stem cell transplantation in Mutliple Myeloma” presented during Conference of Multiple Myeloma: State of the Art 2016, Chandigarh, India
7. “Cytogenetic and Molecular Profile of Acute Myeloid Leukaemia in India” presented during 54th National Conference of Indian Society of Hematology & Transfusion Medicine (ISHTM)-2013, Mumbai, India.
8. “Bortezomib plus Dexamethasone Induction Followed by Autologous Stem Cell Transplantation in Multiple Myeloma: A Study from India” presented during 54th National Conference of Indian Society of Hematology & Transfusion Medicine (ISHTM)-2013 Mumbai, India.
9. “Expression of CD20 in precursor B-cell acute lymphoblastic leukemia – An analysis of 100 cases” presented during 52nd National Conference of Indian Society of Hematology & Transfusion Medicine (ISHTM)-2011, Chandigarh, India.

10. “Profile of serum immunofixation electrophoresis in Multiple Myeloma – A study in a Tertiary Care centre” presented during 52nd National Conference of Indian Society of Hematology & Transfusion Medicine (ISHTM)-2011, Chandigarh, India.

PUBLICATIONS

1. **Kumar J**, Radhakrishnan VS, Nair R, Bhav S, Chandy M et al. Blastic Plasmacytoid Dendritic Cell Neoplasm in a Young Female: Rare and Challenging. *Indian Journal of Medical and Pediatric Oncology*. 2020. DOI: 10.4103/ijmpo.ijmpo_143_19
2. **Kumar J**, Nair R, Radhakrishnan VS, Bhav S, Chandy M et al. Autologous stem cell transplantation in Multiple Myeloma: experience of a single center from Eastern India. *Clinical Lymphoma, Myeloma & Leukemia*, 2019. 19: S124-S176. <https://doi.org/10.1016/j.clml.2019.07.393>
3. **Kumar J**, Nair R, Radhakrishnan VS, Bhav S, Chandy M et al. Single center analysis of chronic myeloid leukemia treatment. *Indian J Hematol Blood Transfus* 33, 1–126 (2017). <https://doi.org/10.1007/s12288-017-0893>
4. **Kumar J**, Nair R, Chakrapani A, Bhav S, Chandy M et al. Single Center Experience with Autologous Stem Cell Transplantation for Multiple Myeloma, a retrospective analysis. *Clinical Lymphoma, Myeloma & leukemia*. Feb 2017, 17; e72
5. Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, **Kumar J**, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. *Lancet*. 2020; 396:1563–1573. doi: 10.1016/S0140-6736(20)32292-3.
6. Ablat O, Cicconi L, Locatelli F, **Kumar J**, Miguel A. Sanz, Francesco Lo Coco; Clinical Characteristics and Treatment Outcome of Acute Myeloid Leukemia with APL-like Morphology and Uncommon *RARA* Fusion Variants. *Blood* 2017; 130 (Supplement 1): 3860. doi: https://doi.org/10.1182/blood.V130.Suppl_1.3860.3860
7. Radhakrishnan VS, Nair R, **Kumar J**, Mallath M. Cachexia at Diagnosis adversely predicts outcomes in patients with Aggressive B-Cell NHL receiving standard of care treatment: A Prospective Observational Study from India. *Blood* 2019; 134 (Supplement_1): 2907. doi: <https://doi.org/10.1182/blood-2019-126295>
8. Kumar M, **Kumar J**, Harishankar A, Bhav S, Nair R, Bhattacharya S, Chandy M. Cytomegalovirus reactivation and disease amongst patients with allogeneic haematopoietic stem cell transplantation in Eastern India: Epidemiology, outcome and healthcare cost. *Indian Journal of Medical Microbiology*. 2018; 36: 1: 49-53

9. **Kumar J**, Minhas S, Khillan K, Bhargava M, Aggarwal S. Bortezomib plus dexamethasone induction followed by autologous stem cell transplantation in multiple myeloma: A study from India. *Asian Journal of Medical Sciences*. 2016; 7 (4): 44-48.
10. Nag, A., Radhakrishnan VS, **Kumar, J**. Chandy M et al. Thalidomide in Patients with Transfusion-Dependent E-Beta Thalassemia Refractory to Hydroxyurea: A Single-Center Experience. *Indian J Hematol Blood Transfus* (2020). <https://doi.org/10.1007/s12288-020-01263-2>
11. Chowdhury MR, **Kumar J**, Chakrapani A, Bhawe S, Krishnan S, Thambudorai R, Bhattacharya S, Chandy M. Low Incidence of Central Venous Catheter-Related Bloodstream Infections in Stem Cell Transplant Patients in Eastern India Despite High Community Burden of Multidrug-Resistant Pathogens. *Infect Control Hosp Epidemiol* 2016; 37:619–620.
12. Nag A, Radhakrishnan VS, **Kumar J**, Chandy M et al. Profile of Acute Graft-versus-Host-Disease of the Gastro-Intestinal Tract following Allogeneic Hematopoietic Cell Transplantation from a Tertiary Care Center in India. *Bone Marrow Transplant* 54, 144–619 (2019). <https://doi.org/10.1038/s41409-019-0559-4>
13. Radhakrishnan VS, Shah S, **Kumar J**, Bhawe S, Nair R, Chandy M et al. Outcomes of high risk myeloid malignancies undergoing Hematopoietic Cell transplant in a tertiary Care facility: real world evidence from India. *Bone Marrow Transplant* 53, 145–805 (2019). <https://doi.org/10.1038/s41409-018-0354-7>
14. Radhakrishnan VS, **Kumar J**, Bhawe S, Nair R, Chandy M et al. T-cell Replete Haploidentical Peripheral blood Hematopoietic cell transplant is associated with high incidence of cytokine release syndrome: Single Centre experience from India. *Bone Marrow Transplant* 53, 145–805 (2019). <https://doi.org/10.1038/s41409-018-0354-7>
15. Shah S, Radhakrishnan VS, **Kumar J**, Bhawe S, Nair R, Chandy M et al. Myeloablative Conditioning Followed By T-Cell Replete Haploidentical Related Donor Peripheral Blood Stem Cell Transplant Using Post-Transplant Cyclophosphamide Immune Tolerance Approach for High Risk Haematological Malignancies: An Indian Perspective. *Biol Blood Marrow Transplant* 24 (2018) S291–S459
16. Gupta N, Parihar M, **Kumar J**, Bhawe S, Chandy M, Mishra D, Arora N et al. FxCycle™ Based Ploidy Correlates with Cytogenetic Ploidy in B-Cell Acute Lymphoblastic Leukemia and Is Able to Detect the Aneuploid Minimal Residual Disease Clone. *Cytometry B Clin Cytom* 2019. 96:5: 359-367.
17. Gupta N , Pawar R, Parihar M, **Kumar J**, Nair R, Chandy M, Arora N, Mishra D et al. Spectrum and Immunophenotypic Profile of Acute Leukemia: A Tertiary Center Flow

Cytometry Experience. *Mediterr J Hematol Infect Dis* 2019, 11(1): e2019017, DOI: <http://dx.doi.org/10.4084/MJHID.2019.017>

18. Modak K, Radhakrishnan VS, **Kumar J**, Nair R, Chandy M et al. Bridging R-ALL (Relapsed / Refractory Acute Lymphoblastic Leukemia) to a Haematopoietic Cell Transplant using Inotuzumab Ozagamycin. *Indian J Hematol Blood Transfus* 34, 1–396 (2018). <https://doi.org/10.1007/s12288-018-1037-7>
19. **Kumar J**, Chakrapani A, Bhawe S, Nair R, Khusoo V, Chitrapur R, Mishra D, Arora N, Parihar M, Chandy M. Autologous stem cell transplantation in Multiple Myeloma: Analysis of 45 patients from a new stem cell unit from Eastern India. (Abstract) 2nd ISHBT-EHA Tutorial on myeloid malignancies and multiple myeloma. 2016.
20. **Kumar J**, Sachdeva A. Monitoring High risk areas: Cancer wards. In: Wattal C, Khardori N eds. *Hospital infection prevention: Principles & Practices*. 1st ed. New Delhi, India: Springer; 2014: 137-142.
21. **Kumar J**, Khan AA, Saraf A, Bhargava M. Expression of CD20 in B cell precursor acute lymphoblastic leukemia. *Indian J Hematol Blood Transfus*. (Jan –Mar) 2014, 30 (1) :16-18; doi: 10.1007/s12288-012-0216-1.
22. **Kumar J**, Arya V, Sachdeva A, Aggarwal S, Bhargava M. Cytogenetic and Molecular Profile of Acute Myeloid Leukaemia in India. *Indian J Hematol Blood Transfus*. 2013; 29(4): 281.
23. **Kumar J**, Bhargava M, Aggarwal S. Bevacizumab-induced reversible thrombocytopenia in a patient with adenocarcinoma of colon: Rare adverse effect of Bevacizumab. *Case Rep Oncol Med*. 2012; doi: 10.1155/2012/695430.
24. **Kumar J**, Khan AA, Kumar V, Bhargava M. Profile of serum immunofixation electrophoresis in Multiple Myeloma – A study in a Tertiary Care centre. *Indian J Hematol Blood Transfus*. 2011; 27(4): 222.
25. **Kumar J**, Singh G, Singh K, Sandhu PS. Evaluation of the efficacy of ramipril versus combination of ramipril and telmisartan in stage II hypertensive patients with microalbuminuria. *Biomedicine*. 2010; 30(3): 340-345.

1. CLINICAL TRIALS

1. Principal Investigator: A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (svd) versus bortezomib and dexamethasone (vd) in patients with relapsed or refractory multiple myeloma (RRMM), Karyopharm [Protocol ID: KCP-330-023]. EC Approval: 11.01.2018

2. Principal Investigator: Real world use of generic Pomalidomide in relapsed/ refractory Multiple Myeloma: A Prospective Phase IV observational study
3. Principal Investigator: Myeloma registry- Indian Myeloma academic groupe (IMAGe) Registry [Multicentric]
4. Co Guide for DNB Thesis: Effect of Pomalidomide- Bortezomib-Dexamethasone Induction on MRD status in patients with newly diagnosed Multiple Myeloma (PRIME Study)
5. Co Investigator for DNB thesis: Acute Myeloid Leukemia: Exploring the feasibility of Multi-modal-Omics based Genomic characterization, MRD evaluation and Computational drug modelling to inform Disease management.
6. Co Investigator: A multicentre retrospective medical record review study to describe real –world treatment patterns and safety among patients receiving Rituximab (Mabthera or Reditux) to treat B cell NHL in India
7. Co Investigator: A Phase 2b Open-Label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. [Protocol ID: KCP-330-009].